Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058 is registered in ClinicalTrials.gov with Sierra Oncology LLC - a GSK company as lead sponsor.

NCT NCT01423058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01423058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Lead sponsor
Sierra Oncology LLC - a GSK company
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2011
Completion date
June 30, 2014
Enrollment
61 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

post-essential thrombocythemia myelofibrosis, post-polycythemia vera, primary myelofibrosis